Difference between revisions of "Part:BBa K2208005:Experience"

 
 
Line 1: Line 1:
 +
===Applications of BBa_K2208003===
  
−
__NOTOC__
+
====Usage and Biology====
−
This experience page is provided so that any user may enter their experience using this part.<BR>Please enter
+
We packaged BCL2 siRNA into exosomes by transfecting HEK293 cells with a plasmid expressing BCL2 siRNA and then collected siRNA-encapsulated exosomes. When modified exosomes being intravenously injected, they will specifically recognize integrin receptors and fuse with white fat adipose cells under the direction of the tPep. Once inside cells, BCL2 siRNA will bind to BCL2 mRNA through base-pairing and digest the mRNA, resulting in sharp decrease of BCL2 protein in white fat adipose cells. As a consequence, BCL2 protein’s reduction and disturbed function will both result in the apoptosis of adipose cells, which ultimately have some therapeutic effects on losing weight.
−
how you used this part and how it worked out.
+
  
−
===Applications of BBa_K2208005===
+
====CHARACTERIZATION====
 +
To ensure the interference efficiency of anti-BCL2 siRNA plasmid, we transfected it into HEK293 cells and then extracted protein from these cells to perform western blot. Significant down-regulation of BCL2 protein can be observed in HEK293 cells treated with anti-BCL2 siRNA, demonstrating that anti-BCL2 siRNA has the gene silencing effect. The siRNA-4 in the picture refers to this part RNA.
 +
 
 +
[[File:NJU_China_iGEM_2017_test0002.jpeg|200px]]
 +
 
 +
Figure 1. Protein quantitatively analysis of BCL2 protein after transfection of BCL2 siRNA
  
 
===User Reviews===
 
===User Reviews===
−
<!-- DON'T DELETE --><partinfo>BBa_K2208005 StartReviews</partinfo>
+
<!-- DON'T DELETE --><partinfo>BBa_K2208003 StartReviews</partinfo>
 
<!-- Template for a user review
 
<!-- Template for a user review
 
{|width='80%' style='border:1px solid gray'
 
{|width='80%' style='border:1px solid gray'
 
|-
 
|-
 
|width='10%'|
 
|width='10%'|
−
<partinfo>BBa_K2208005 AddReview number</partinfo>
+
<partinfo>BBa_K2208003 AddReview number</partinfo>
 
<I>Username</I>
 
<I>Username</I>
 
|width='60%' valign='top'|
 
|width='60%' valign='top'|
Line 18: Line 23:
 
|};
 
|};
 
<!-- End of the user review template -->
 
<!-- End of the user review template -->
−
<!-- DON'T DELETE --><partinfo>BBa_K2208005 EndReviews</partinfo>
+
<!-- DON'T DELETE --><partinfo>BBa_K2208003 EndReviews</partinfo>

Latest revision as of 14:37, 27 October 2017

Applications of BBa_K2208003

Usage and Biology

We packaged BCL2 siRNA into exosomes by transfecting HEK293 cells with a plasmid expressing BCL2 siRNA and then collected siRNA-encapsulated exosomes. When modified exosomes being intravenously injected, they will specifically recognize integrin receptors and fuse with white fat adipose cells under the direction of the tPep. Once inside cells, BCL2 siRNA will bind to BCL2 mRNA through base-pairing and digest the mRNA, resulting in sharp decrease of BCL2 protein in white fat adipose cells. As a consequence, BCL2 protein’s reduction and disturbed function will both result in the apoptosis of adipose cells, which ultimately have some therapeutic effects on losing weight.

CHARACTERIZATION

To ensure the interference efficiency of anti-BCL2 siRNA plasmid, we transfected it into HEK293 cells and then extracted protein from these cells to perform western blot. Significant down-regulation of BCL2 protein can be observed in HEK293 cells treated with anti-BCL2 siRNA, demonstrating that anti-BCL2 siRNA has the gene silencing effect. The siRNA-4 in the picture refers to this part RNA.

NJU China iGEM 2017 test0002.jpeg

Figure 1. Protein quantitatively analysis of BCL2 protein after transfection of BCL2 siRNA

User Reviews

UNIQ383a754b95885425-partinfo-00000000-QINU UNIQ383a754b95885425-partinfo-00000001-QINU